Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, presented NeuLogiq® ...

is targeting amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND), and potentially other ...

The approval makes Relyvrio (sodium phenylbutyrate and taurursodiol) the first new therapy option for ALS – also known as motor neuron disease ... An open-label extension revealed that ALS ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

The phase III trial COURAGE-ALS of investigational reldesemtiv, a fast skeletal troponin activator, did not meet its primary ...

The 25-year-old finished with 198 metres, 22 runs, 10 tackle busts, five offloads, two line breaks and 29 tackles in a savage all-round display that prompted NRL halfback great Greg Alexander to label ...

This open-label trial assessed the therapy’s efficacy ... root cause of SMA by substituting the nonworking survival motor neuron 1 (SMN1) gene with one dose. In October 2024, the company ...

All assessments were performed in a blinded fashion. Table 1. Quantification of spinal motor neuron labeling in animals with labeling restricted to first-order motor neurons only following rabies ...

The paper describes a novel approach for inferring features of synaptic networks from recordings of individual cells within the network. The paper will be a valuable contribution to those studying ...

The open-label Phase 1/2 study, called EPISOD1 (NCT06100276) is intended to… People with diabetes or high cholesterol may be less likely to develop amyotrophic lateral sclerosis (ALS) or other motor ...